Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


About us

The MEDtalks Group publish independent global expert perspectives on the latest clinical practice changing studies, across multiple therapeutic areas, and provide local relevance for healthcare professionals. 


Login Register

Featured Articles

Congress news 22/06/2020

European clinicians share their local perspectives on practice changing studies from EHA25 Virtual

MEDtalks in association with The European Hematology Association has launched a series of four webinars, covering some of the most important practice changing studies presented at EHA25 Virtual. We invited leading European clinicians and study authors from the UK, Germany, Spain, the Netherlands and Switzerland to discuss the relevance of these studies for their local clinical practice. The webinar series was divided into the following topics: Multiple Myeloma & CAR-T, Lymphoma, CLL and AML. You can watch the webinars below: Multiple myeloma & CAR-T Webinar Lymphomas Webinar CLL Webinar AML Webinar All webinars are moderated by PD Dr. med. Jens Ulrich Rüffer. The webinars are independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: Multiple Myeloma & CAR-T

In this webinar, Prof. Dr. John Gribben, Prof. Dr. Valentín Ortiz and PD Prof. Dr. Dr. Udo Holtick discuss three practice changing studies on Multiple Myeloma/CAR-T. Study 1 summarised by Prof. Dr. John Gribben IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL Study 2 summarised by Prof. Dr. Valentín Ortiz IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS Study 3 summarised by PD Prof. Dr. Dr. Udo Holtick LB2603 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: CLL

In this webinar, Prof. Dr. Arnon Kater, Prof. Dr. Clemens Wendtner and Prof. Dr. Davide Rossi discuss three practice changing studies on CLL. Study 1 summarised by Prof. Dr. Arnon Kater EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I) Study 2 summarised by Prof. Dr. Clemens Wendtner S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL Study 3 summarised by Prof. Dr. Davide Rossi S 158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: Lymphomas

In this webinar, Prof. Dr. Peter Borchmann and Dr. Robert Marcus discuss three practice changing studies on Lymphomas. Study 1 summarised by Prof. Dr. Peter Borchmann (S101) POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG and INTERIM ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (CARON A. JACOBSON) Study 2 summarised by Dr. Robert Marcus ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA)   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: AML

In this webinar, Prof. Dr. Nigel Russel, MD and Prof. Dr. Gert Ossenkoppele discuss two practice changing studies on AML. Study 1 summarised by Prof. Dr. Nigel Russell MD (S144) THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS Study 2 summarised by Prof. Dr. Gert Ossenkoppele (LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

ASCO Discussion Round I: Highlights from a European Perspective

In this discussion, round experts from Switzerland and Germany discuss practice-changing studies with the ASCO2020 original authors.  The following authors are presenting their studies:    Dr. Fatima Cardoso         Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients   Dr. Javier Cortes Breast Cancer Program, IOB Institute of Oncology, Madrid & Barcelona, Spain                      KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.   Prof. Dr. Andreas du Bois Department Gynecology & Gyn.Oncology KEM, Evang. Kliniken Essen-Mitte gGmbH, Essen, Germany Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round II: Highlights from a European Perspective

In this second round table discussion, experts from Switzerland and Germany discuss practice-changing studies in the fields of Head & Neck Tumors and Lung Cancer with the ASCO2020 original authors.  The following authors are presenting their studies:  Prof. Dr. Kevin Joseph Harrington The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, United Kingdom KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).            Prof. Dr. Martin Reck LungenClinic Grosshansdorf, Grosshansdorf, Germany Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.   Prof. Dr. Joel Guigay                 Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, France TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   John Kuruvilla, MD (Dr.) Princess Margaret Cancer Centre, Toronto, ON, Canada KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round III: Highlights from a European Perspective

In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.  The following authors are presenting their studies:  Dr. Thierry André Sorbonne University and Saint-Antoine Hospital, Paris, France Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study   Prof. Dr. Shaji Kumar Mayo Clinic, Rochester, MN, USA Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.   Dr. Landon Carter Brown Duke Cancer Institute, Durham, North Carolina, USA Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.   Dr. Jesus G. Berdeja Sarah Cannon Research Institute, Nashville, TN, USA Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.   Prof. Dr. Thomas Powles Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

E-learnings 21/01/2020

Treatment of advanced melanoma

Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted therapy and immunotherapy. Now, we finally have five-year survival data for both kinds of treatments. How do these results impact daily clinical practice? MEDtalks brings you an on demand e-learning (recorded on January 21st, 2020), in which a Belgian expert panel discusses first and second line treatment of advanced melanoma with targeted therapy and immunotherapy. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial is of course not left untouched: should patients be treated with combination immunotherapy or monotherapy? And besides this systemic armamentarium, what is the role of local treatment options in the current treatment of (brain) metastasized melanoma? Panel members Prof. Bart Neyns, MD, PhD - medical oncologist, University Hospital of Brussels Prof. Vibeke Kruse, MD, PhD - medical oncologist, Ghent University Annemie Rutten, MD, PhD - medical oncologist, GZA Hospital Sint-Augustinus Prof. Dirk van Gestel, MD, PhD - radiation oncologist, Institut Jules Bordet Subjects (among others) Five-year survival rate of targeted therapy and immunotherapy;   First and second line systemic treatment of advanced melanoma; Combination immunotherapy versus monotherapy anti-PD1 subsequently followed by anti-CTLA4; Management of patients with poor prognostic factors (e.g. brain metastases) with both systemic and local therapy. This e-learning is accredited for Dutch oncologists (1 CME point). We are requesting accreditation for medical oncologists in Belgium. Points are credited as soon as accreditation has been granted.